Pancreatitis Cell Models for Research

Acute pancreatitis (AP) has a global incidence of approximately 34 per 100,000 person-years, with mortality ranging from 1-2% for mild cases to 20-30% for severe cases (WHO, 2023). Chronic pancreatitis (CP) affects about 50 per 100,000 adults, with a 5-year survival rate of 70-80% and a 10-year survival of 50-60% (NCI SEER, 2023). Key risk factors include gallstones, alcohol abuse, smoking, genetic mutations (PRSS1, SPINK1, CFTR, CTRC), and autoimmune conditions. The economic burden exceeds $2.5 billion annually in the US alone. Pancreatitis is a major risk factor for pancreatic ductal adenocarcinoma (PDAC), with chronic pancreatitis increasing PDAC risk 5-15 fold. The 5-year survival for PDAC remains below 10%, underscoring the need for early intervention and mechanistic research.

Pancreatitis serves as an ideal model for mechanistic studies due to its well-defined genetic subtypes, accessible clinical samples, and progression to fibrosis and cancer. Key research questions include: how do trypsinogen activation and calcium signaling trigger acinar cell injury? What role do immune cells play in the transition from acute to chronic disease? How do genetic mutations in PRSS1, SPINK1, and CFTR contribute to disease onset? Public datasets such as TCGA-PAAD, GEO, and ClinVar provide rich genomic and transcriptomic data. The disease offers a window into inflammation-driven carcinogenesis, making it valuable for drug discovery and biomarker development.

1. Premature trypsinogen activation pathway:

• • PRSS1 mutations lead to autoactivation of trypsinogen within acinar cells.
• • SPINK1 mutations impair trypsin inhibition, causing autodigestion.
• • Calcium overload and cathepsin B activation further amplify injury.

2. Unfolded protein response (UPR) and ER stress:

• • Accumulation of misfolded proteins triggers PERK, ATF6, and IRE1 pathways.
• • Chronic ER stress promotes acinar cell death and inflammation.

3. NF-kB and inflammatory signaling:

• • Cytokine release (TNF-alpha, IL-6, IL-1beta) recruits immune cells.
• • Sustained inflammation leads to fibrosis and pancreatic stellate cell activation.

4. Fibrosis and carcinogenesis:

• • TGF-beta and PDGF drive stellate cell proliferation and collagen deposition.
• • KRAS mutations cooperate with inflammation to initiate PDAC.

Data from TCGA, COSMIC, and ClinVar.

• • Calcium signaling:
• • IP3 receptors and CRAC channels mediate calcium overload.
• • Calmodulin-dependent kinase II (CaMKII) activates NF-kB.
• • MAPK/ERK pathway:
• • RAS-RAF-MEK-ERK cascade promotes inflammation and proliferation.
• • Activated by KRAS mutations and cytokine receptors.
• • PI3K/AKT/mTOR pathway:
• • Supports cell survival and metabolism.
• • Frequently activated in pancreatitis-associated cancer.
• • Wnt/beta-catenin pathway:
• • Regulates acinar-to-ductal metaplasia.
• • Aberrant activation in chronic pancreatitis.
• • JAK/STAT pathway:
• • Cytokine-driven STAT3 activation promotes fibrosis.
• • Crosstalk with NF-kB amplifies inflammation.

Organoids derived from patient biopsies or genetically engineered mouse models offer advantages: they recapitulate 3D architecture, retain genetic heterogeneity, and enable long-term culture. They are ideal for studying acinar-to-ductal metaplasia, drug response, and CRISPR screens.

• • Patient-derived xenografts (PDX):
• • Implant patient tumor fragments into immunodeficient mice.
• • Preserve tumor heterogeneity and drug response.
• • Genetically engineered mouse models (GEMM):
• • KrasG12D; Pdx1-Cre (KC) model develops PanIN and PDAC.
• • Cerulein-induced acute pancreatitis model.
• • PRSS1 R122H knock-in mice.
• • Induced models:
• • Caerulein hyperstimulation to induce acute pancreatitis.
• • L-arginine or duct ligation for chronic pancreatitis.
• • Alcohol and high-fat diet models.

CRISPR-Cas9 is used to create isogenic cell lines with specific mutations or knockouts. Examples include:

• • PRSS1 R122H knock-in in AR42J or HPDE cells to model hereditary pancreatitis.
• • SPINK1 knockout in PANC-1 or hTERT-HPNE cells to study trypsin inhibition loss.
• • CFTR F508del knock-in in Capan-1 or HPDE cells to model ductal dysfunction.
• • KRAS G12D knock-in in HPNE cells to study early carcinogenesis.
• • TP53 knockout in PANC-1 to assess chemoresistance.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, validated tools. These models enable precise mechanistic studies and drug screening without the variability of primary cells. Custom services for generating such lines are available from specialized providers.

Knockout and knock-in lines validate gene function in disease pathways. For example:

• • SPINK1 knockout in HPNE cells increases trypsin activity and acinar injury markers.
• • PRSS1 R122H knock-in in AR42J cells shows enhanced calcium signaling and NF-kB activation.
• • CFTR knockout in Capan-1 cells impairs ductal bicarbonate secretion.

These models allow systematic interrogation of gene-gene interactions and pathway crosstalk.

Isogenic pairs (wild-type vs. mutant) enable high-throughput screening for compounds that selectively target mutant cells. Examples:

• • KRAS G12D vs. wild-type HPNE cells for KRAS inhibitor testing.
• • TP53 knockout vs. wild-type PANC-1 for chemosensitivity assays.
• • PRSS1 mutant vs. wild-type for anti-inflammatory drug screening.

Resistance modeling: repeated exposure to gemcitabine in TP53 knockout lines reveals resistance mechanisms.

CRISPR synthetic lethality screens identify vulnerabilities in mutant backgrounds. For example:

• • Genome-wide knockout screen in KRAS G12D HPNE cells identifies dependencies on metabolic enzymes.
• • CRISPR interference (CRISPRi) screens in PRSS1 mutant lines reveal modifiers of trypsin activation.
• • These screens yield candidate biomarkers for early detection and therapeutic targets.